- Home
- ALNY vs BSBR Comparison
ALNY vs BSBR Comparison
Compare ALNY & BSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- BSBR
- Stock Information
- Founded
- ALNY 2002
- BSBR 1985
- Country
- ALNY United States
- BSBR Brazil
- Employees
- ALNY N/A
- BSBR N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- BSBR Commercial Banks
- Sector
- ALNY Health Care
- BSBR Finance
- Exchange
- ALNY Nasdaq
- BSBR Nasdaq
- Market Cap
- ALNY 42.9B
- BSBR 36.4B
- IPO Year
- ALNY 2004
- BSBR 2009
- Fundamental
- Price
- ALNY $458.28
- BSBR $4.77
- Analyst Decision
- ALNY Strong Buy
- BSBR Strong Buy
- Analyst Count
- ALNY 27
- BSBR 2
- Target Price
- ALNY $401.92
- BSBR $6.00
- AVG Volume (30 Days)
- ALNY 1.3M
- BSBR 562.3K
- Earning Date
- ALNY 07-31-2025
- BSBR 07-30-2025
- Dividend Yield
- ALNY N/A
- BSBR 4.46%
- EPS Growth
- ALNY N/A
- BSBR 27.22
- EPS
- ALNY N/A
- BSBR 0.36
- Revenue
- ALNY $2,461,963,000.00
- BSBR $9,124,703,234.00
- Revenue This Year
- ALNY $33.75
- BSBR N/A
- Revenue Next Year
- ALNY $31.66
- BSBR N/A
- P/E Ratio
- ALNY N/A
- BSBR $6.97
- Revenue Growth
- ALNY 5.01
- BSBR 11.13
- 52 Week Low
- ALNY $205.87
- BSBR $3.75
- 52 Week High
- ALNY $462.88
- BSBR $5.77
- Technical
- Relative Strength Index (RSI)
- ALNY 85.86
- BSBR 40.22
- Support Level
- ALNY $421.81
- BSBR $4.94
- Resistance Level
- ALNY $445.20
- BSBR $5.07
- Average True Range (ATR)
- ALNY 17.25
- BSBR 0.09
- MACD
- ALNY 3.15
- BSBR 0.02
- Stochastic Oscillator
- ALNY 95.92
- BSBR 24.42
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About BSBR Banco Santander Brasil SA each representing one unit
Banco Santander (Brasil) SA is part of Santander Group, a Spanish bank. It operates across two segments; the Commercial Banking segment, catering to both individual and corporate client and the Global Wholesale Banking segment, which encompasses Investment Banking and Markets operations, including the Treasury and Equity Business Departments. The bank generates majority of its revenue from the Commercial Banking segment and has operations in Brazil and internationally.